Menopause: Perimenopause, Symptoms, Hormone Therapy, and Non-Hormonal Options

Introduction

Menopause is the permanent cessation of menstruation resulting from loss of ovarian follicular activity. It is diagnosed retrospectively after 12 consecutive months of amenorrhea (without other cause). Average age of natural menopause is 51 years (range 45-55). The menopausal transition (perimenopause) typically begins 4-8 years before final menses.

Stages of Reproductive Aging (STRAW+10 Criteria)

Stage	Description	Duration	Key Characteristics
-5	Early reproductive	Variable	Regular cycles
-4	Peak reproductive	Variable	Regular cycles
-3a	Early late reproductive	2-6 years	Minor cycle length changes (1-2 days)
-3b	Later late reproductive		Montly cycle variability
-2	Early menopause transition	1-3 years	Variable cycle length (>7 days difference from normal)
-1	Late menopause transition	1-2 years	2+ skipped cycles and 60+ day amenorrhea
+1a	Early postmenopause	1 year	From FMP to 12 months
+1b	Early postmenopause	1-6 years	Rapid bone loss, vasomotor symptoms peak
+1c	Late postmenopause	5-8 years	Continuing symptoms for some women
+2	Late postmenopause	Rest of life	Symptoms decline; increasing chronic disease risk

Perimenopause

Hormonal Changes

Hormone	Early Perimenopause	Late Perimenopause	Postmenopause
FSH	Normal to elevated (variable)	Elevated (>25 IU/L)	High (>40 IU/L)
Estradiol	Normal to elevated (fluctuating)	Decreasing	Low (<15 pg/mL)
Progesterone	Declining	Low	Very low
AMH	Low	Very low	Undetectable (correlates with ovarian reserve)
Inhibin B	Low	Very low	Undetectable

Signs of Perimenopause

Sign	Description	Timing
Cycle irregularity	Shorter cycles initially; then longer, skipped cycles	Earliest sign (mid-late 40s)
Hot flashes/flushes	Sudden warmth, sweating, flushing (face, neck, chest)	Begins in late perimenopause; most common 1-2 years after FMP
Sleep disturbance	Difficulty falling/staying asleep, night sweats	Related to vasomotor symptoms; may persist
Vaginal dryness	Decreased lubrication, dyspareunia	Progressive; peaks years after FMP
Mood changes	Irritability, depression risk, anxiety	May be related to sleep disruption
Cognitive changes	“Brain fog,” mild memory issues	Usually transient
Weight gain	Central adiposity accumulation	Metabolic changes

Menopausal Symptoms

Vasomotor Symptoms (Hot Flashes and Night Sweats)

Aspect	Details
Prevalence	60-80% of women (may last 5-10 years)
Quality	Sudden sensation of heat, upper body/face, with sweating, palpitations, anxiety
Duration	1-10 minutes
Frequency	Variable: few/week to 20+/day
Triggers	Warm environment, hot drinks, spicy foods, alcohol, caffeine, stress
Impact	Sleep disruption, impaired quality of life
Course	Most bothersome in first 1-2 years postmenopause; gradually decline

Genitourinary Syndrome of Menopause (GSM)

Symptom	Prevalence	Description
Vaginal dryness	50%+	Decreased lubrication, burning, irritation
Dyspareunia	30-50%	Pain with intercourse
Urinary frequency	20-40%	Increased urge and frequency
Urgency	20-40%	Sudden strong urge to urinate
Recurrent UTIs	15-25%	Increased UTI risk
Vulvar atrophy	30-40%	Thinning, pallor, decreased elasticity

Sleep Disturbance

Aspect	Detail
Prevalence	40-60% in perimenopause and early postmenopause
Contributing factors	Night sweats (most common), mood changes, nocturia, RLS
Pattern	Difficulty falling asleep, frequent awakenings (especially due to sweats), early morning awakening
Consequences	Daytime fatigue, mood changes, cognitive impairment

Mood and Cognition

Symptom	Frequency	Contributing Factors	Management
Depressive symptoms	15-30% (higher risk in perimenopause)	Hormonal fluctuations, sleep disruption, life stressors	CBT, SSRIs/SNRIs, sleep management
Irritability	30-50%	Sleep deprivation, hot flashes	HRT (if vasomotor symptoms contribute)
Anxiety	20-40%	Hormonal changes, sleep, life stressors	CBT, SSRIs, buspirone, relaxation
Brain fog / memory	40-60% (self-reported)	Sleep disruption, hormonal changes	Usually resolves; HRT may help perimenopausally

Other Symptoms

Symptom	Prevalence	Management
Joint and muscle pain	40-50%	Exercise, weight management, NSAIDs
Headaches	20-30%	Standard headache management
Skin/hair changes	30-50%	Thinning skin, hair loss; moisturizers, biotin
Weight gain / metabolic changes	50%+	Diet, exercise, monitor glucose and lipids
Osteoporosis risk	Increases	Calcium + vitamin D, weight-bearing exercise, DEXA screening

Hormone Replacement Therapy (HRT)

Benefits vs Risks

Outcome	Evidence	Estrogen Alone	Estrogen + Progestin
Vasomotor symptoms	Strong	Effective (75-90% reduction)	Effective
GSM	Strong	Effective (local or systemic)	Effective
Bone density	Strong	Increases BMD; 30-40% fracture reduction	Same
Sleep quality	Moderate	Improves	Improves
Mood	Moderate	Improves perimenopausal depression	Same
Cognition (timing hypothesis)	Moderate	May benefit if start near menopause; may harm if start >65	Same
Venous thromboembolism	Strong	Oral: 2x risk (low with transdermal)	Similar
Stroke	Strong	Oral: 1.3x risk	1.3x risk
Breast cancer	Strong	<5 years: no significant risk; >5 years: possible minimal increase	1.25x risk (5 years); 1.55x risk (>5 years)
Coronary heart disease	Strong	<60 years or <10 years since menopause: no increased risk; may decrease	<60 years: no significant risk
Endometrial cancer (with estrogen alone in non-hysterectomized)	Strong	High risk (5-8x)	Prevented by progestin
Ovarian cancer	Moderate	1.2x risk (long-term)	Same
Gallbladder disease	Strong	1.5-2x risk	Same

HRT Regimens

Type	Components	Indications	Advantages	Disadvantages
Systemic estrogen (ET)	Oral or transdermal estradiol (17-beta) or conjugated equine estrogen	Vasomotor symptoms, prevention of bone loss	Most effective for vasomotor symptoms; bone protection	Requires progestin if uterus intact
Combined estrogen + progestin (EPT)	ET + progestin (medroxyprogesterone, micronized progesterone) or tissue-selective (bazedoxifene)	Vasomotor symptoms with intact uterus (prevent endometrial cancer)	Cyclic or continuous; continuous preferred after menopause	Breast tenderness, bleeding patterns, PMS-like symptoms
Low-dose vaginal estrogen	Cream, tablet, ring, or ovule	GSM only	Minimal systemic absorption; no progestin needed	Only treats GSM; not for vasomotor symptoms
Tibolone (not in US)	Synthetic steroid	Vasomotor + libido	Improves both	Limited availability

HRT Formulations

Route	Examples	Advantages	Disadvantages
Oral	Estradiol, CEE, estradiol + progesterone	Convenient, multiple options, lipid effects	First-pass metabolism, VTE risk (higher than transdermal)
Transdermal patch	Estradiol patch (Climara, Vivelle, generic)	Lower VTE risk; stable levels	Skin irritation; adhesion issues
Transdermal gel/spray	Estradiol gel (EstroGel, Divigel), spray (Evamist)	Lower VTE risk; flexible dosing	Messy; transfer risk
Vaginal ring (Estring, Femring)	Low-dose (Estring: GSM only); higher dose (Femring: systemic + GSM)	Long-acting; continuous release	Insertion/removal; expensive
Vaginal cream (Estrace, Premarin)	Low-dose	Targeted delivery; flexible dosing	Messy; absorption may vary
Vaginal tablet (Vagifem, Yuvafem)	Low-dose estradiol	Convenient; minimal mess	Insertion device; less flexible dosing

Progestins Used with Estrogen Therapy

Progestin	Formulation	Bleeding Profile	Metabolic Effects
Micronized progesterone (Prometrium)	Oral capsule 100-200 mg, vaginal	Less irregular bleeding	Sleep aid; no adverse lipid effects; anti-androgen
Medroxyprogesterone acetate (Provera)	Oral 2.5-5 mg	Good cycle control	Adverse lipid effects (HDL lowering); mood changes more common
Norethindrone acetate (Aygestin)	Oral 0.35-1 mg	Good	Less adverse effect than MPA
Levonorgestrel IUD (Mirena)	Intrauterine	Minimal systemic	Best for endometrial protection, no systemic progestin effects
Drospirenone (Angeliq)	Oral 0.25-0.5 mg	Good	Anti-androgen, anti-mineralocorticoid (BP neutral)

WHI Study Key Findings

Aspect	Finding
Population	27,347 women, mean age 63 (50-79)
Estrogen + progestin (E+P) trial	Stopped early (2002): increased breast cancer, CHD, stroke, VTE; decreased hip fracture, colorectal cancer
Estrogen alone (E) trial	Stopped early (2004): no increase in breast cancer; increased stroke; decreased hip fracture
Reanalysis (age-stratified)	Women 50-59: no increase in CHD; benefit for all-cause mortality in E-alone arm
Timing hypothesis	Starting HRT <10 years from menopause may have CV benefit; starting >10-20 years may increase risk
Current consensus	HRT is appropriate for symptom management in women <60 or <10 years from menopause; lowest effective dose; individualized

USMSTF / NAMS HRT Recommendations

Scenario	Recommendation
Vasomotor symptoms (age <60, <10 years from menopause)	HRT first-line (systemic estrogen +/- progestin)
Vasomotor symptoms (age >60, >10 years from menopause)	Non-hormonal options first; lowest dose HRT if needed
GSM only	Vaginal estrogen first-line (no systemic progestin needed)
Osteoporosis prevention (symptomatic)	HRT appropriate for bone + symptom benefit
Osteoporosis prevention (asymptomatic)	Other options (bisphosphonates, RANKL inhibitors, SERMs) preferred
Breast cancer survivors	Avoid systemic HRT; use vaginal estrogen cautiously
Premature ovarian insufficiency (<40)	HRT recommended until average age of menopause (51)

Non-Hormonal Treatment Options

Vasomotor Symptoms

Agent	Dose	Efficacy (reduction in hot flash frequency/severity)	Side Effects
Venlafaxine (Effexor) SNRI	37.5-75 mg ER daily	40-60%	Nausea, insomnia, sexual dysfunction
Paroxetine (Brisdelle) SSRI	7.5 mg daily (FDA-approved)	40-50%	Nausea, headache, sexual dysfunction; FDA-approved for VMS
Gabapentin (Neurontin)	300-900 mg at night or BID-TID	40-60%	Dizziness, sedation, weight gain
Pregabalin (Lyrica)	75-150 mg BID	30-50%	Same as gabapentin
Clonidine (patch or oral)	0.1-0.2 mg/day transdermal or 0.1-0.2 mg PO BID	30-40%	Dry mouth, dizziness, hypotension
Oxybutynin	2.5-5 mg BID or ER	50-70% (emerging)	Dry mouth, anticholinergic effects
Fezolinetant (Veozah)	45 mg daily (FDA-approved)	50-60%	Headache, insomnia; NK3 receptor antagonist

GSM (Non-Hormonal)

Product	Type	Mechanism	Use
Vaginal moisturizers (Replens, HyaloGyn)	Bioadhesive gel	Hydrate vaginal tissue, lower pH	2-3 times/week
Vaginal lubricants (water-based, silicone-based)	Personal lubricant	Reduce friction	With sexual activity
Ospemifene (Osphena)	Oral SERM	Estrogen-like effect on vaginal tissue	60 mg daily
CO2 fractional laser	Laser treatment	Remodels vaginal epithelium	3 treatments; limited evidence
Radiofrequency	Energy treatment	Collagen stimulation	Limited evidence

Sleep

Approach	Options
Non-pharmacologic	CBT-I (first-line), sleep hygiene, exercise
Melatonin	0.5-3 mg (limited evidence for benefit)
Low-dose doxepin (Silenor)	3-6 mg at night
Trazodone	25-50 mg at night
Gabapentin	100-300 mg at night
Treat underlying VMS	HRT or non-hormonal options for night sweats

Osteoporosis and Menopause

Aspect	Recommendation
DEXA screening	Starting at age 65; earlier if risk factors
Calcium	1,200 mg/day (diet + supplement combined)
Vitamin D	800-1,000 IU/day
Weight-bearing exercise	30-40 minutes, 4+ times/week
Smoking cessation	Reduces bone loss
Limit alcohol	<2 drinks/day
Pharmacologic treatment	Bisphosphonates, raloxifene, denosumab, teriparatide, romosozumab